Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Zevra Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Zevra Therapeutics, Inc.’s stock price such as:

• Zevra Therapeutics, Inc.’s current stock price and volume
• Why Zevra Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ZVRA from analysts
• ZVRA’s stock price momentum as measured by its relative strength

About Zevra Therapeutics, Inc. (ZVRA)

Before we jump into Zevra Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Want to learn more about Zevra Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Zevra Therapeutics, Inc..

Zevra Therapeutics, Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Zevra Therapeutics, Inc.’s stock price was $12.400.

Zevra Therapeutics, Inc. is down 1.12% from its previous closing price of $12.540.

During the last market session, Zevra Therapeutics, Inc.’s stock traded between $12.200 and $12.650. Currently, there are approximately 59.16 million shares outstanding for Zevra Therapeutics, Inc..

Zevra Therapeutics, Inc.’s price-earnings (P/E) ratio is currently at 12.9, which is low compared to the Pharmaceuticals industry median of 17.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Zevra Therapeutics, Inc. Stock Price History

Zevra Therapeutics, Inc.’s (ZVRA) price is currently up 5.62% so far this month.

During the month of September, Zevra Therapeutics, Inc.’s stock price has reached a high of $12.650 and a low of $11.560.

Over the last year, Zevra Therapeutics, Inc. has hit prices as high as $15.035 and as low as $7.160. Year to date, Zevra Therapeutics, Inc.’s stock is up 38.39%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Zevra Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there was 1 analyst who downgraded Zevra Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Zevra Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Zevra Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Zevra Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Zevra Therapeutics, Inc. (ZVRA) by visiting AAII Stock Evaluator.

Relative Price Strength of Zevra Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Zevra Therapeutics, Inc. has a weighted four-quarter relative price strength of 3.26%, which translates to a Momentum Score of 65 and is considered to be Strong.

Want to learn more about how Zevra Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Zevra Therapeutics, Inc. Stock Price: Bottom Line

As of September 4, 2026, Zevra Therapeutics, Inc.’s stock price is $12.400, which is down 1.12% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Zevra Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.